On February 18, the FHE2025 Boao Food for Health Science Conference&Expo officially opened in Boao, Hainan. With the theme of "New Productive Forces Leading the Development of the Health Food Industry," the conference brought together authoritative experts, research institutions, and industry elites from around the world to engage in in-depth discussions on cutting-edge developments and innovation trends in the health food industry. As a pioneer in the HMO (Human Milk Oligosaccharides) industry, Henglu Bio was invited to attend and was awarded the "Technological Progress Enterprise Award" for its outstanding technological innovation capabilities. Additionally, Professor Fang Xu, Chairman and Chief Scientist of Henglu Bio, shared insights at the special forum titled "A New Chapter in HMO Frontier Research and Market Application," presenting third-generation HMO synthesis technology driven by synthetic biology, which brought new perspectives and solutions to the industry.

Exhibition Highlights

On the afternoon of the 17th, Professor Fang Xu introduced the core values of HMO and Henglu Bio's patented technologies to the experts and scholars visiting Henglu's exhibition booth. He engaged in an in-depth discussion with experts and scholars regarding the technical advantages of HMO and its extensive applications in the health food sector, showcasing Henglu Bio's profound technical expertise and global perspective in the HMO field.

Moment of Honor

At the banquet on the evening of the 18th, Henglu Bio received the "Technological Progress Enterprise Award" for its technological innovations and industrialization achievements in the HMO field. This honor recognizes Henglu Bio's years of dedication to the HMO sector and highlights its significant contributions to advancing technology within the health food industry.

Keynote Speech

On the morning of the 20th, Professor Fang Xu delivered a speech at the forum "A New Chapter in HMO Frontier Research and Market Application," discussing "Synthetic Biology-Driven Third Generation HMO Synthesis Technology: From Laboratory to Industrialization." He elaborated on the critical role of artificial intelligence in HMO production and proposed innovative solutions to address the current oversupply situation of whey in the market.

Professor Fang Xu pointed out that Henglu Bio employs a BT (Biotechnology) + IT (Information Technology) model using yeast methods to produce HMO, replacing lactose with whey as a raw material. This technology not only effectively reduces resource waste but also significantly lowers production costs, while enhancing the value-added of the products, bringing substantial economic benefits to the industry chain. This innovative practice paves new pathways for the industrialization of HMO and provides a referable model for the global health food industry.

Henglu Bio remains focused on human and animal nutrition, diligently conducting R&D on HMO technology and committing to the development of a full range of HMO products. As an industry-leading raw material supplier, Henglu Bio not only offers high-quality HMO raw materials to the market but also provides customized solutions for clients, supporting the sustainable development of the health food industry.